The exercise of warrants provides Silexion Therapeutics with additional capital, which is crucial for a clinical-stage biotech company. This influx of funds can support ongoing research and development activities, potentially accelerating progress in their RNAi therapies. The market may view this positively as it strengthens the company's financial position.